Product Information
NAPROXEN 125 MG/5 ML SUSPEN is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.2018 per ML under NDC 70954015110. Its NADAC has been published 133 times since Mar 20, 2024.
FDA first approved this application on Mar 10, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
125 mg/5mL
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954015110
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NAPROXENApproval Type
Generic (ANDA)
FDA Application
ANDA211910FDA Approved
3/10/2021
TE Code
AB
On Market Since
3/12/2021
Pharmacological Classes
Price Statistics
The NADAC for NAPROXEN 125 MG/5 ML SUSPEN has been published 133 times since Mar 20, 2024, and over the history we have for it it has declined 78.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2018 per ML |
|---|---|
| All-time high | $0.9187 (Apr 10, 2024) |
| All-time low | $0.1654 (Mar 18, 2026) |
| 52-week high | $0.2346 |
| 52-week low | $0.1654 |
| Median price | $0.2841 |
| Average price | $0.3533 |
| Largest weekly change | -33.2% (Oct 23, 2024) |
| Weeks tracked | 133 |
| Tracking since | Mar 20, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Naproxen oral market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Naproxen oral market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NAPROXEN 125 MG/5 ML SUSPEN?
The current National Average Drug Acquisition Cost (NADAC) for NAPROXEN 125 MG/5 ML SUSPEN, manufactured by ANI Pharmaceuticals, Inc., is $0.2018 per ML (NDC 70954015110), effective Sep 30, 2026.
How has the price of NAPROXEN 125 MG/5 ML SUSPEN changed over time?
Over the history we have for it, the NADAC for NAPROXEN 125 MG/5 ML SUSPEN has declined 78.0%. It has been tracked across 133 weekly CMS publications since Mar 20, 2024.
What are the highest and lowest recorded NADAC prices for NAPROXEN 125 MG/5 ML SUSPEN?
Since Mar 20, 2024, the NADAC for NAPROXEN 125 MG/5 ML SUSPEN has ranged from a low of $0.1654 (Mar 18, 2026) to a high of $0.9187 (Apr 10, 2024), with a median of $0.2841 per ML.
Are there cheaper alternatives to NAPROXEN 125 MG/5 ML SUSPEN?
No other NADAC-published product currently shares the active ingredient and strength of NAPROXEN 125 MG/5 ML SUSPEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NAPROXEN 125 MG/5 ML SUSPEN?
NAPROXEN 125 MG/5 ML SUSPEN (NDC 70954015110) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.